Bexsero

Australia approves meningococcal B vaccine

Thursday, 15 August 2013

The Therapeutic Goods Administration has licensed the Novartis meningococcal B vaccine Bexsero for use in Australia.

The next steps will involve the Australian Technical Advisory Group on Immunisation making recommendations of who should receive the vaccine on the National Immunisation Programme to the Minister for Health and Ageing, and Novartis working with regulatory authorities to make the vaccine available for private purchase in Australia.

Meningococcal disease in Australia is predominantly caused by serogroup B. In contrast, most meningococcal disease in New Zealand is caused by serogroup B or serogroup C.

Show in archive
Archived: 
0
Archive Date: 
Audience: 

Meningococcal B vaccine shows promise

Tuesday, 24 January 2012

The pharmaceutical company Novartis is expected to license the 4CMenB vaccine overseas in the next few months.

Vaccines for meningococcal groups A, C, Y and W135 are already available but due to the unique nature of the meningococcal B bacteria a vaccine against it has been difficult to develop.

 

Chilean-led researchers have trialled the 4CMenB vaccine, also known as Bexsero, in infants, toddlers and adolescents and shown the vaccine to be safe and effective in preventing meningococcal B disease.

 

Meningococcal disease is caused by the bacteria Neisseria meningitidis. Five meningococcal groups, A, B, C, Y and W135, typically cause disease in people. In New Zealand over the last 4 years groups B and C have been the cause of most cases of the disease.

 

The disease is serious and tends to progress rapidly causing blood infection (septicaemia) or infection of the layers over the brain (meningitis).

Show in archive
Archived: 
0
Archive Date: 
Audience: 

New meningococcal B vaccine in Europe

Friday, 25 January 2013

The European Commission has approved a new vaccine (Bexsero®) that provides broad protection against meningococcal group B disease.

In Europe, the vaccine has been licensed for use in individuals two months of age and older. The Therapeutic Goods Administration (TGA) in Australia is also reviewing the vaccine data and considering licensure of Bexsero® in Australia.

Bexsero® will complement the currently available meningococcal group C and groups A, C, Y and W-135 vaccines currently available.

Information about the disease is available on our Meningococcal disease webpage and in our fact sheet.

Show in archive
Archived: 
0
Archive Date: 
Audience: 
Subscribe to RSS - Bexsero